Research Topics
Species | Andreas EngertSummaryAffiliation: University of Cologne Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trialAndreas Engert
University Hospital of Cologne, Department of Internal Medicine I, Koln, Germany
Lancet 379:1791-9. 2012..We did a prospective randomised clinical trial comparing two reduced-intensity chemotherapy variants with our previous standard regimen. Chemotherapy was followed by PET-guided radiotherapy...- Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trialAndreas Engert
University Hospital of Cologne, Department of Internal Medicine, Kerpener Str 62, Cologne, Germany 50924
J Clin Oncol 28:2239-45. 2010.... 
Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic reviewJulia Bohlius
Department of Internal Medicine I, University of Cologne, Germany
Br J Haematol 122:413-23. 2003..However, there is no evidence that G-CSF/GM-CSF improved CR and OS in this clinical setting...- Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphomaAndreas Engert
Klinik I fur Innere Medizin, Klinikum der Universität zu Köln, Cologne, Germany
Onkologie 32:599-604. 2009.... - Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 studyAndreas Engert
Klinik I fur Innere Medizin, Universitätsklinik Köln, Kerpener Strasse 62, 50931 Koln, Germany
J Clin Oncol 27:4548-54. 2009..The previous analysis with 5 years median follow-up had indicated improved tumor control with BEACOPP escalated. Since the long-term safety and efficacy of this regimen has been debated, we report the 10-year follow-up... - Recombinant human erythropoietin in oncology: current status and further developmentsA Engert
Klinik I fur Innere Medizin, Universitätsklinikum Köln, Koln, Germany
Ann Oncol 16:1584-95. 2005..In addition, very recent results of a Food and Drug Administration meeting on safety and survival of patients treated with erythropoietin are presented... - Reduced treatment intensity in patients with early-stage Hodgkin's lymphomaAndreas Engert
Department of Internal Medicine, University of Cologne, Cologne, Germany
N Engl J Med 363:640-52. 2010.... - Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trialAndreas Engert
First Department of Internal Medicine, Coordination Center for Clinical Trials, and Department of Radiotherapy, University Hospital of Cologne, Cologne, Germany
J Clin Oncol 25:3495-502. 2007.... - Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study GroupAndreas Engert
Department of Internal Medicine, University of Cologne, Kerpener Str 62, 50924 Cologne, Germany
J Clin Oncol 23:5052-60. 2005..We thus performed a retrospective analysis using the German Hodgkin's Study Group (GHSG) database to determine clinical risk factors, course of treatment, and outcome in elderly HL patients in comparison with younger adults... - XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapyA Engert
Department of Internal Medicine, University Clinic of Cologne, Germany
Leuk Lymphoma 50:374-9. 2009..Treatment with XM02 is as beneficial as filgrastim in ameliorating severe neutropenia and FN in patients with NHL receiving chemotherapy. XM02 is safe and well tolerated in the doses applied in this study... - [Role of high-dose chemotherapy in hematology and internal medicine/ oncology]A Engert
Klinik I fur Innere Medizin, Universitat zu Koln
Med Klin (Munich) 94:431-42. 1999..The authors give an overview of the current role of HDCT in lympho-hematopoietic malignancies and solid tumors... - Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphomaR Schnell
Klinik I fuer Innere Medizin, Universitaet zu Koeln, 50924 Koeln, Germany
Ann Oncol 14:729-36. 2003..Both ITs showed potent specific activity against HL cells in vitro and in vivo in animal models, and were subsequently evaluated in phase I/II clinical trials in humans... - The emerging role of ricin A-chain immunotoxins in leukemia and lymphomaA Engert
Department I for Internal Medicine, University of Cologne, Germany
Curr Top Microbiol Immunol 234:13-33. 1998..Most clinical trials performed with ITs so far were conducted in heavily pretreated patients presenting with high tumor burdens. Thus, the responses observed with ITs in these trials are very encouraging and warrant further exploration... - Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II studyAndreas Engert
Department I of Internal Medicine, University of Cologne, Cologne, Germany
Haematologica 91:546-9. 2006..Toxicities were mostly moderate in intensity. These results support the feasibility of delivering full dose, on schedule BEACOPP-14, chemotherapy with pegfilgrastim support... - Fourth biannual report of the Cochrane Haematological Malignancies GroupThilo Kober
Cochrane Haematological Malignancies Group, Cologne, Germany
J Natl Cancer Inst 98:E1. 2006 - Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study GroupKarolin Behringer
First Department of Internal Medicine, University Hospital Cologne, Joseph Stelzmann Str 9, 50924 Cologne, Germany
J Clin Oncol 23:7555-64. 2005..Among these, infertility for female patients is of major importance. The subject of this analysis is to evaluate the menstrual status after HL therapy... - A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German HodgkiHans Theodor Eich
Department of Radiation Oncology, University of Cologne, Cologne, Germany
Int J Radiat Oncol Biol Phys 69:1187-92. 2007..A quality control program based on a multidisciplinary panel of radiation oncologists, radiologists, and medical oncologists who reviewed all patients' staging and restaging imaging was initiated... - Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trialBastian Von Tresckow
University of Cologne, Cologne, Germany
J Clin Oncol 30:907-13. 2012..We aimed to improve these results using more intensive chemotherapy... - Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study GroupAndreas Josting
First Department of Internal Medicine, University Hospital Cologne, Joseph Stelzmann Str 9, 50924 Cologne, Germany
J Clin Oncol 23:1522-9. 2005..To evaluate treatment outcome and prognostic factors in patients with refractory or first relapsed Hodgkin's disease (HD) treated with salvage radiotherapy (SRT) alone... - Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphomaKathrin Bauer
Cochrane Haematological Malignancies Group, First Department of Internal Medicine, University Hospital of Cologne, Kerpener Strasse 62, D 50924 Cologne, Germany
J Natl Cancer Inst 102:E1. 2010.... - Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study GroupHans Theodor Eich
Department of Radiation Oncology, University of Cologne, Cologne, Germany
Int J Radiat Oncol Biol Phys 63:860-5. 2005.... - Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)Teresa V Halbsguth
First Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany
Blood 116:2026-32. 2010..Three patients died before response assessment. Thus, the BACOPP regimen is active in older HL patients but is compromised by a high rate of toxic deaths. This trial was registered at www.clinicaltrials.gov as #NCT00284271... - Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's LymphAndreas Engert
Department I of Internal Medicine, University Hospital Cologne, Cologne 50924, Germany
J Clin Oncol 21:3601-8. 2003..CONCLUSION: Radiotherapy volume size reduction from EF to IF after COPP + ABVD chemotherapy for two cycles produces similar results and less toxicity in patients with early-stage unfavorable HD... 
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphomaCarsten Kobe
Department of Nuclear Medicine, University of Cologne, Cologne, Germany
Blood 112:3989-94. 2008..Until then, response adapted therapy guided by PET for HL patients seems to be a promising approach that should be further evaluated in clinical trials. This trial is registered at http://isrctn.org study as #ISRCTN32443041...- Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study GroupHans Theodor Eich
Department of Radiation Oncology, University of Cologne, Cologne, Germany
Int J Radiat Oncol Biol Phys 58:1121-7. 2004..The purpose of the present investigation was to assess the feasibility of such a procedure and its impact on the final definition of disease extension and patient treatment... - Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trialHans Theodor Eich
University of Cologne, German Hodgkin Study Group, Koln, Germany
J Clin Oncol 28:4199-206. 2010..It is unclear whether treatment results can be improved with more intensive chemotherapy and which radiation dose needs to be applied... - Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphomaBoris Boll
Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany
Blood 118:6292-8. 2011..We conclude that PVAG is safe and feasible in elderly HL patients. This trial was registered at www.clinicaltrials.gov as #NCT00147875... - Current treatment and immunotherapy of Hodgkin's lymphomaBeate Klimm
Department I of Internal Medicine, University Hospital Cologne, 50924 Cologne, Germany
Haematologica 90:1680-92. 2005..Radioimmunoconjugates and monoclonal antibodies have demonstrated some clinical efficacy. Here, we review new aspects in the treatment of primary and relapsed Hodgkin's lymphoma as well as recent immunotherapeutic approaches... - Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patientsJulia Bohlius
Department of Internal Medicine I, University of Cologne, Germany
J Natl Cancer Inst 98:708-14. 2006..08, 95% CI = 0.99 to 1.18; 42 trials and 8167 patients). Caution is advised when using epoetin or darbepoetin in combination with thrombogenic chemotherapeutic agents or for cancer patients who are at high risk for thrombo-embolic events... - Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)Holger Schulz
Department I of Internal Medicine, University of Cologne, Cologne, Germany
Blood 111:109-11. 2008..Thus, rituximab is highly effective in relapsed and refractory NLPHL. This study is registered at http://www.klinisches-studienzentrum.de/trial/285... - Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial oPeter Borchmann
University Hospital of Cologne, Kerpener Str 62, 50924 Cologne, Germany
J Clin Oncol 29:4234-42. 2011..However, treatment-related toxicity is a concern, and the role of RT in this setting is unclear. The HD12 study thus aimed to reduce toxicity while maintaining efficacy... - Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG)Michal Sieniawski
Department of Internal Medicine, University Hospital Cologne, Cologne, Germany
Blood 111:71-6. 2008..Male patients with HL are at high risk of infertility after treatment with BEACOPP... - Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination oHenning Bredenfeld
Department I for Internal Medicine, University Hospital Cologne, Cologne, Germany
J Clin Oncol 22:2424-9. 2004.... - 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study GroupM Sieber
German Hodgkin s Lymphoma Study Group, Klinik fur Innere Medizin, University of Cologne, Germany
J Clin Oncol 21:1734-9. 2003.... - Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cellsElke Pogge von Strandmann
Department of Internal Medicine I, University Hospital of Cologne, Kerpener Str 62, D 50924 Cologne, Germany
Immunity 27:965-74. 2007..We propose a concept for target cell recognition by NK cells beyond "missing self" and "induced self," mediated through a tumor cell-derived extracellular factor... - Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitorsNicole Skoetz
Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
J Natl Cancer Inst 103:E1. 2011.... - Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphomaKatrin S Reiners
Laboratory of Immunotherapy, Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany
J Immunother 32:508-12. 2009..On the basis of these results, a prospective clinical study has been initiated to further investigate the impact of this antiangiogenic approach in HL... - Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study GroupLucia Nogova
First Department of Internal Medicine, University Hospital Cologne, Kerpenerstr 62, 50924 Cologne, Germany
J Clin Oncol 26:434-9. 2008..To shed more light on the prognosis and outcome of LPHL, we reviewed all LPHL patients registered in the German Hodgkin Study Group (GHSG) database, comparing patient characteristics and treatment outcome with cHL patients... - Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5Markus Sieber
German Hodgkin s Lymphoma Study Group, Cologne, Germany
J Clin Oncol 20:476-84. 2002.... - Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysisHolger Schulz
Cochrane Haematological Malignancies Group, Clinic I of Internal Medicine I, University of Cologne, Kerpenerstrasse 62, D 50924 Cologne, Germany
J Natl Cancer Inst 99:706-14. 2007.... - Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study GroupB Klimm
Department I of Internal Medicine, University Hospital Cologne, Germany
Ann Oncol 18:357-63. 2007..Since many of these patients receive combined modality treatment, we evaluated the impact of different radiation field sizes, that is extended-field (EF) or involved-field (IF) technique when given after four cycles of chemotherapy... - The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosisBoris Boll
University Hospital of Cologne, Department of Internal Medicine, Kerpener Str 62 D 50924 Köln, Germany
Blood 106:1839-42. 2005..We conclude that initial 5F11-mediated NF-kappaB signaling sensitizes the tumor cells to bortezomib-induced cell death. These data suggest a therapeutic value of this combination for HD patients... - Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicityBoris Boll
Laboratory of Immunotherapy, Department of Hematology and Oncology, University Hospital Cologne, Cologne, Germany
Clin Cancer Res 15:5108-16. 2009..The molecular chaperone heat shock protein 90 (HSP90) has immune regulatory activity and supports the activation of NF-kappaB in Hodgkin's lymphoma cells... - A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivoElke Pogge Von Strandmann
Laboratory of Immunotherapy, Department I for Internal Medicine, University Hospital of Cologne, Kerpener Str 62, D 50924 Koln, Germany
Blood 107:1955-62. 2006..The use of recombinant NK receptor ligands that target NK cells to tumor cells might offer new approaches for other malignancies provided a tumor antigen-specific antibody is available... - Third biannual report of the Cochrane Haematological Malignancies GroupThilo Kober
Cochrane Haematological Malignancies Group, Cologne, Germany
J Natl Cancer Inst 97:E2. 2005 - Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long-term survival in patients with aggressive malSusanne Rödel
Department I of Internal Medicine, University of Cologne, Germany
Leuk Lymphoma 46:1729-34. 2005..ACOMED followed by involved field radiation presents a highly effective regimen for remission induction and long-term survival in patients with aggressive NHL, and merits further investigation... - Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibodyRoland Schnell
Department of Internal Medicine I, Department of Nuclear Medicine, University of Cologne, Germany
J Clin Oncol 23:4669-78. 2005..Response included one complete remission, five partial remissions, and three minor responses. CONCLUSION: Treatment with (131)I-Ki-4 is effective but can be associated with severe hematotoxicity... - Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trialM Sieber
Klinik I fur Innere Medizin, University of Cologne, Cologne, Germany
Ann Oncol 15:276-82. 2004.... - Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's LymphomaRoland Schnell
Department I of Internal Medicine, University of Cologne, Germany
Onkologie 31:49-51. 2008..Thus, only very limited data of cHL patients treated with anti- CD20 immunoconstructs are available. To date, none of the patients treated with 90Y ibritumomab tiuxetan demonstrated any response... - Lymphocyte-depleted classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin study groupBeate Klimm
University Hospital of Cologne, Cologne, Germany
J Clin Oncol 29:3914-20. 2011..To investigate the clinical characteristics and treatment outcome of patients with lymphocyte-depleted classical Hodgkin's lymphoma (LDCHL) compared with other histologic subtypes of Hodgkin's lymphoma (HL)... - Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicityStefan Wilde
Department of Pharmacology, University Hospital, University of Cologne, Cologne, Germany
Clin Pharmacokinet 46:319-33. 2007..The present study was conducted to address the role of pharmacokinetics in individual toxicity... - Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphomaPeter Borchmann
Klinik I fur Innere Medizin, Universitat Koln, Koln, Germany
Leuk Lymphoma 52:620-8. 2011..Symptomatic cardiac failure occurred in four patients; however, pre-existing conditions confounded causality... - Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphomaMichal Sieniawski
Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany
Ann Hematol 86:107-15. 2007..However, only prospective randomized trial can offer sufficient data of the value of rituximab in relapsed and refractory aggressive NHL... - The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphomaPeter Borchmann
Klinik I für Innere Medizin der Universität Köln, Joseph Stelzmann Strasse 9, 50924 Cologne, Germany
Blood 102:3737-42. 2003..Based on these results, a clinical phase 1 study in patients with refractory CD30+ lymphoma has been initiated... - A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)V Ballova
Department of Internal Medicine I, University Hospital of Cologne, Cologne and the German Hodgkin Lymphoma Study Group, Germany
Ann Oncol 16:124-31. 2005..Hodgkin-specific FFTF at 5 years was 55% after COPP-ABVD and 74% after BEACOPP (P=0.13). Thus, there are no differences in survival between these regimens in elderly patients... - Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study groupDennis A Eichenauer
First Department of Internal Medicine, University Hospital of Cologne, Kerpener Str 62, 50924 Cologne, Germany
J Clin Oncol 27:6079-85. 2009..These data suggest that adult treatment protocols exhibit a safe and effective treatment option for adolescent patients with HL. However, longer follow-up, including assessment of late toxicity, is necessary for final conclusions... - Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphomaJan-Peter Glossmann
First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany
Ann Hematol 84:517-25. 2005..Tandem HDCT followed by autologous stem cell transplantation (ASCT) offers a chance of cure in these poor prognostic patients, but is associated with risks... - Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphomaAndreas Josting
University of Cologne, German Hodgkin Study Group, Koln, Germany
J Clin Oncol 28:5074-80. 2010..The intensity of treatment needed is unclear. This European intergroup study evaluated the impact of sequential high-dose chemotherapy (SHDCT) before myeloablative therapy... - The role of PET in Hodgkin's lymphoma and its impact on radiation oncologyCarsten Kobe
Department of Nuclear Medicine, University Hospital of Cologne, Germany
Expert Rev Anticancer Ther 10:1419-28. 2010.... - Nodular lymphocyte-predominant Hodgkin's lymphomaLucia Nogova
First Department of Internal Medicine, University Hospital Cologne, Kerpenerstr 62, 50924 Cologne, Germany
Curr Hematol Malig Rep 1:60-5. 2006.... - The HD12 panel of the German Hodgkin Lymphoma Study Group (GHSG): a quality assurance program based on a multidisciplinary panel reviewing all patients' imagingHans Theodor Eich
Department of Radiotherapy, University of Cologne, Germany
Am J Clin Oncol 27:279-84. 2004..Patients with Hodgkin disease receive high-quality CT imaging. A central independent multidisciplinary panel markedly improves quality assurance for these study patients... - Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trialThomas Elter
Department of Hematology and Oncology, University of Cologne, Cologne, Germany
J Clin Oncol 23:7024-31. 2005..Two subclinical cytomegalovirus reactivations occurred. CONCLUSION: The new FluCam regimen is effective and feasible in patients with relapsed and refractory B-CLL... - Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study GroupUte Rehwald
Department I of Internal Medicine, University of Cologne, Germany
Blood 101:420-4. 2003..The median duration of response has not been reached yet (20+ months). We conclude that rituximab is both safe and effective in a subgroup of CD20(+) patients with HD... - Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivoBaerbel Matthey
, Cologne, Germany
Int J Cancer 111:568-74. 2004..Thus, concomitant application of metalloproteinase inhibitors might become clinically relevant in antibody-based immunotherapy against targets known to be shed from tumor cells... - Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trialsAlexander Shimabukuro-Vornhagen
First Department of Internal Medicine, University Hospital Cologne, Joseph-Stelzmann-Str 9, 50924 Cologne, Germany
J Clin Oncol 23:5739-45. 2005..It is associated with an excellent prognosis if treated with current treatment regimens. When treating patients with LRCHL, great attention should be paid to avoid acute toxicities... - Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer functionVenkateswara Rao Simhadri
Laboratory of Immune Therapy, Department of Internal Medicine I, Centre for Integrated Oncology Koeln Bonn, University of Cologne, Cologne, Germany
PLoS ONE 3:e3377. 2008..The manipulation of the exosomal regulation may offer a novel strategy to induce tumor immunity or inhibit autoimmune diseases caused by NK cell-activation... - Fludarabine in chronic lymphocytic leukaemiaThomas Elter
First Department of Internal Medicine, University of Cologne, Joseph Stelzmann Str 9, 50924 Cologne, Germany
Expert Opin Pharmacother 7:1641-51. 2006.... - Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trialsM Sieniawski
Department of Internal Medicine, University Hospital Cologne, Cologne, Germany
Ann Oncol 19:1795-801. 2008..Infertility is one of the most significant side-effects in long-term survivors of successfully treated Hodgkin's lymphoma (HL)... - Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapyChristian Straka
Schön Klinik Starnberger See, Berg, Germany, and Medizinische Klinik Innenstadt der Universität München, Munich, Germany
Blood 117:2121-8. 2011..0001). G-CSF responsiveness appears as a signature of the myeloid marrow reserve predicting defense against neutropenic infection after intensive chemotherapy. This study is registered at http://www.clinicaltrials.gov as NCT01085058... - Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic reviewChristine Herbst
Department I of Internal Medicine, Cochrane Haematological Malignancies Group CHMG, University Hospital Cologne, Kerpener Strasse 62, 50924 Cologne, Germany
Haematologica 95:494-500. 2010..These trials underlined the results of the main analysis. In conclusion, adding radiotherapy to chemotherapy improves tumor control and OS in patients with early stage Hodgkin's lymphoma... - Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysisJulia Bohlius
Department of Internal Medicine I, University of Cologne, Cologne, Germany
J Natl Cancer Inst 97:489-98. 2005.... - Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinomaRon D Jachimowicz
Department I of Internal Medicine, University Hospital Cologne, LFI, Ebene 4, Room 703, Kerpener Str 62, 50927 Cologne, Germany
Mol Cancer Ther 10:1036-45. 2011..Finally, the efficacy of a multimeric immunoligand is shown in a prostate carcinoma mouse xenograft model showing a strong activity against advanced established tumors... - Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell linesFriederike Heuck
Laboratory of Immunotherapy, Department I for Internal Medicine, University Hospital Cologne, Cologne, Germany
J Immunother (1997) 27:347-53. 2004..The data suggest that the combination of the human antibody 5F11 with conventional chemotherapy might be beneficial in the combined chemo-immunotherapy of CD30-positive lymphomas... - Combined modality treatment of Hodgkin's lymphomaBeate Klimm
From the Department I of Internal Medicine and the German Hodgkin s Study Group GHSG, University Hospital Cologne, Germany
Cancer J 15:143-9. 2009..Here, we review results from current clinical trials and discuss new therapeutic approaches in the combined modality treatment of HL... - Treatment of lymphocyte-predominant Hodgkin lymphomaA Engert
Department of Internal Medicine 1, University of Cologne, Cologne, Germany
Ann Oncol 19:iv45-6. 2008 - Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study GroupBeate Klimm
First Department of Internal Medicine, University Hospital Cologne, Germany
J Clin Oncol 23:8003-11. 2005..In future trials, this therapy may be tailored in a response-adapted manner depending on the individual toxicity profile within the first cycles... - Sixth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin lymphomaOlaf Weingart
Cochrane Haematological Malignancies Group Department of Internal Medicine 1, University Hospital of Cologne, Kerpener Street 62, D-50924 Cologne, Germany
J Natl Cancer Inst 99:E1. 2007 - Depletion of cellular cholesterol and lipid rafts increases shedding of CD30Bastian Von Tresckow
Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany
J Immunol 172:4324-31. 2004..Our results suggest a possible role of cholesterol-dependent shedding of CD30 in the pathogenesis of immune diseases... - New strategies for the treatment of advanced-stage Hodgkin's lymphomaVolker Diehl
Department of Internal Medicine I, Haus Lebenswert, University Hospital of Cologne, Kerpenerstr 62, 50931 Cologne, Germany
Hematol Oncol Clin North Am 21:897-914. 2007..With this individualized approach it might be possible to yield higher cure rates and simultaneously reduce the risk for late complications and mortality... - Simvastatin-dependent apoptosis in Hodgkin's lymphoma cells and growth impairment of human Hodgkin's tumors in vivoBastian Von Tresckow
Laboratory of Immunotherapy, Clinic I of Internal Medicine, University Hospital Cologne, Cologne, Germany
Haematologica 92:682-5. 2007..Since the prenylation-inhibitors FTI-277 and GGTI-298 were also effective against HL-cells, we conclude that statins and specific prenylation-inhibitors should be evaluated in HL patients... - An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximabJ Boye
Clinic I of Internal Medicine, University Hospital of Cologne, Germany
Ann Oncol 14:520-35. 2003..The monoclonal antibody is generally well tolerated. Most adverse events are infusion-associated, including chills, fever and rigor related to the release of cytokines... - A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's diseasJ-P Glossmann
First Department of Internal Medicine, University Hospital Cologne, Joseph-Stelzmann-Str. 9, 50931 Cologne, Germany
Ann Hematol 81:424-9. 2002 - A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphomaRoland Schnell
Department of Internal Medicine I, University of Koeln, Joseph-Stelzmann-Strasse 9, D-50924 Koeln, Germany
Clin Cancer Res 8:1779-86. 2002..This might be because of the low number of CD30+ peripheral blood mononuclear cells, and in part because of binding of the IT to soluble CD30 antigen and the resulting circulation of IT/sCD30 complexes... - Current strategies of antibody-based treatment in Hodgkin's diseaseR Schnell
, , Germany
Ann Oncol 13:57-66. 2002..Future phase III trials will have to prove a possible superior effect of this combined immunochemotherapy. Currently, the evaluation of the most promising approaches continues... - Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemiaHolger Schulz
Clinic I of Internal Medicine, University of Cologne, Cologne 50924, Germany
Blood 100:3115-20. 2002..The median duration of response was 75 weeks. We conclude that the combination of rituximab and fludarabine is feasible and effective in patients with B-CLL... - Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panningA Klimka
Department of Internal Medicine I, University Hospital Cologne, Germany
Br J Cancer 83:252-60. 2000.... - High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysisAlexander Greb
Department of Internal Medicine I, University of Cologne, Cologne, Germany
Cancer Treat Rev 33:338-46. 2007..Randomized controlled trials (RCTs) reported conflicting results on the impact of high-dose chemotherapy (HDCT) and autologous stem cell transplantation in the first-line treatment of patients with aggressive non-Hodgkin lymphoma (NHL)... - Eighth biannual report of the Cochrane Haematological Malignancies Group--focus on chronic lymphatic leukemiaChristine Herbst
Department of Internal Medicine 1, Cochrane Haematological Malignancies Group, University Hospital of Cologne, Cologne, Germany
J Natl Cancer Inst 100:E1. 2008 - An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell lineA Klimka
Department of Internal Medicine I, University Hospital Cologne, Germany
Br J Cancer 80:1214-22. 1999..This recombinant immunotoxin is a promising candidate for further clinical evaluation in patients with Hodgkin's lymphoma or other CD30+ malignancies... - Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II studyB Coiffier
Service d Hematologie, Centre Hospitalier Lyon Sud, Pierre Benite, France the Service d Hématologie, Hopital Henri Mondor, Creteil, France the Klinik 1 fur Innere Medezin, Universitat zu Koln, Koln, Germany
Blood 92:1927-32. 1998..Rituximab has significant activity in DLCL and MCL patients and should be tested in combination with chemotherapy in such patients... - Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximabH Pels
Clinic I for Internal Medicine, University of Cologne, Germany
J Neurooncol 59:213-6. 2002..Efficacy and pharmacokinetics of rituximab in PCNSL should be investigated in future trials... - Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemiaMarkus Jensen
University of Cologne, Kerpener Strasse 62, 50924, Cologne, Germany
Invest New Drugs 26:139-49. 2008..Further study of R-etodolac as a possible new maintenance therapy or as a part of combination therapy of B-CLL appears warranted... - Biannual report of the Cochrane Haematological Malignancies GroupSven Trelle
Cochrane Haematological Malignancies Group, Cologne, Germany
J Natl Cancer Inst 96:E2. 2004 - [New therapeutic strategies for Hodgkin lymphoma in cooperation of radiation oncology and medical oncology]Hans Theodor Eich
Klinik und Poliklinik für Strahlentherapie der Universität zu Köln, Germany
Rontgenpraxis 55:114-24. 2003..Actually the GHSG evaluates the efficacy of risk-adapted therapy composed of polychemotherapy (CT) and radiotherapy (RT). An extensive RT quality assurance program has been practiced during the study generations and will be continued... - Second biannual report of the Cochrane Haematological Malignancies GroupThilo Kober
Cochrane Haematological Malignancies Group, Cologne, Germany
J Natl Cancer Inst 97:E1. 2005 - A consumer network for haematological malignanciesNicole Skoetz
Cochrane Haematological Malignancies Group, First Department of Internal Medicine, University of Cologne, , Germany
Health Expect 8:86-90. 2005 - New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study groupAndreas Josting
First Department of Internal Medicine, University Hospital Cologne, Joseph Stelman Strasse 9, 50924 Cologne, Germany
J Clin Oncol 20:221-30. 2002..To evaluate salvage treatment outcome of patients with relapsed Hodgkin's disease (HD) and to distinguish different risk groups using identified prognostic factors... - First-line treatment of Hodgkin's lymphomaBeate Klimm
First Department of Internal Medicine, University Hospital Cologne, Herderstr 52, 50931 Cologne, Germany
Curr Hematol Rep 4:15-22. 2005..Here, we review recent approaches in the first-line treatment of early-favorable, early-unfavorable, and advanced-stage HL... - Selective killing of B-cell hybridomas targeting proteinase 3, Wegener's autoantigenKatrin S Reiners
Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany
Immunology 112:228-36. 2004..The data indicate that autoantigen-toxins are promising tools in the treatment or co-treatment of autoimmune diseases in which the antigen is known... - Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study GroupAndreas Josting
First Department of Internal Medicine, University Hospital Cologne, Joseph Stelzmann Str 9, 50924 Cologne, Germany
J Clin Oncol 21:3440-6. 2003..To assess the incidence and outcome of secondary acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in patients with Hodgkin's disease (HD)... - Prolonged remission in a patient with relapsed follicular lymphoma after a single course of rituximabMarkus Jensen
Department of Internal Medicine I, University of Cologne, Germany
Onkologie 29:90-2. 2006..Rituximab monotherapy can achieve remissions of up to 80% in follicular lymphoma. As the antibody has only been on the market since 1997, long-term observations are still rare...